

Please type a plus sign (+) inside this box →



Substitute for form 1449/A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/589,288
				Filing Date	June 8, 2000
				First Named Inventor	Guo-Liang Yu
				Group Art Unit	1647
				Examiner Name	Bridget E. Bunner
				Attorney Docket Number	702041
				Client Reference No.	PF343P3C5
Sheet	1	of	4		

U.S. PATENT DOCUMENTS						
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
	U I	60/122,388		Yu et al.	N/A	
	U J	60/543,261		Yu et al.	N/A	
	U K	60/580,387		Yu et al.	N/A	
	U L	60/617,191		Yu et al.	N/A	
	U M	60/649,478		Rosenblum et al.	N/A	
	U N	11/054,539		Yu et al.	8/25/2005	
	U O	11/345,661		Rosenblum et al.	8/3/2006	
	U P	5,416,202		Bernhard et al.	5/16/1995	

OTHER - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.			Translation *
	UQ	Yu Priority Statement filed in Patent Interference 105,652. Filed in the United States Patent Office on January 23, 2009.			
	UR	Yu Substantive Motion 1 filed in Patent Interference 105,652. Filed in the United States Patent Office on January 23, 2009.			
	US	Rosenblum Preliminary Motion 1 filed in Patent Interference 105,652. Filed in the United States Patent Office on January 23, 2009.			
	UT	Rosenblum Re-filed Preliminary Motion 1 filed in Patent Interference 105,652. Filed in the United States Patent Office on January 23, 2009.			
	UU	Rosenblum Substantive Motion 2 filed in Patent Interference 105,652. Filed in the United States Patent Office on January 23, 2009.			
	UV	Yu Responsive Motion 2 filed in Patent Interference 105,652. Filed in the United States Patent Office on February 19, 2009.			
	UW	Yu Opposition 1 filed in Patent Interference 105,652. Filed in the United States Patent Office on April 1, 2009.			
	UX	Yu Opposition 2 filed in Patent Interference 105,652. Filed in the United States Patent Office on April 1, 2009.			
	UY	Rosenblum Opposition 1 filed in Patent Interference 105,652. Filed in the United States Patent Office on April 1, 2009.			
	UZ	Rosenblum Opposition 2 filed in Patent Interference 105,652. Filed in the United States Patent Office on April 1, 2009.			
	VA	Yu Reply 1 filed in Patent Interference 105,652. Filed in the United States Patent Office on April 24, 2009.			
	VB	Yu Reply 2 filed in Patent Interference 105,652. Filed in the United States Patent Office on April 24, 2009.			
	VC	Rosenblum Reply 1 filed in Patent Interference 105,652. Filed in the United States Patent Office on April 24, 2009.			
	VD	Rosenblum Reply 2 filed in Patent Interference 105,652. Filed in the United States Patent Office on April 24, 2009.			

Examiner Signature	Date Considered
--------------------	-----------------

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Please type a plus sign (+) inside this box →




Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/589,288
				Filing Date	June 8, 2000
				First Named Inventor	Guo-Liang Yu
				Group Art Unit	1647
				Examiner Name	Bridget E. Bunner
				Attorney Docket Number	702041
Sheet	2	of	4	Client Reference No.	PF343P3C5

VE	List of Exhibits filed in Patent Interference 105,652, including the corresponding PTO Form-1449 Doc. No. for each exhibit.	
VF	Application File for US Provisional Application 60/225,628 filed in Patent Interference 105,652 (HGS Exhibit 2001).	
VG	Application File for US Application 09/929,493 filed in Patent Interference 105,652 (HGS Exhibit 2002).	
VH	Application File for US Provisional Application 60/336,726 filed in Patent Interference 105,652 (HGS Exhibit 2003).	
VI	Application File for US application 10/270,487 filed in Patent Interference 105,652 (HGS Exhibit 2004).	
VJ	Application File for US Provisional Application 60/543,261 filed in Patent Interference 105,652 (HGS Exhibit 2005).	
VK	Application File for US Provisional Application 60/580,387 filed in Patent Interference 105,652 (HGS Exhibit 2006).	
VL	Helmkamp et al., "High Specific Activity Iodination of γ -Globulin with Iodine-131 Monochloride," <i>Cancer Res.</i> , 20:1495-1500 (1960). Filed in Patent Interference 105,652 (HGS Exhibit 2010).	
VM	Langone, "Radioiodination by Use of the Bolton-Hunter and Related Reagents" <i>Methods in Enzymology</i> , 70:221-247 (1980). Filed in Patent Interference 105,652 (HGS Exhibit 2011).	
VN	Office Communication mailed June 23, 2008 in the HGS Involved Application. Filed in Patent Interference 105,652 (HGS Exhibit 2014).	
VO	Printouts from RDF Technologies, Inc. webpage. Filed in Patent Interference 105,652 (HGS Exhibit 2015).	
VP	Executed Declaration and Information Disclosure Statement date-stamped April 12, 2006 from Application File of the RDF Involved Application. Filed in Patent Interference 105,652 (HGS Exhibit 2016).	
VQ	Riccobene et al., "Rapid and Specific Targeting of 125I-Labeled B Lymphocyte Stimulator to Lymphoid Tissues and B Cell Tumors in Mice," <i>J. Nuc. Med.</i> , 44(3):422-433 (March 2003). Filed in Patent Interference 105,652 (HGS Exhibit 2019).	
VR	Murray et al., "Variables Influencing Tumor Uptake of Anti-Melanoma Monoclonal Antibodies Radiolabeled Using Para-Iodobenzoyl (PIB) Conjugate," <i>J. Nucl. Med.</i> , 32(2) 279-287 (February 1991). Filed in Patent Interference 105,652 (HGS Exhibit 2020).	
VS	Lyu et al., "The Growth Factor Toxin Construct rGel/BLyS Specifically Targets Tumor Cells Expressing BAFF-R, TACI, and BCMA," Abstract 1517, Am. Assoc. for Cancer Res. 96th Annual Meeting, Anaheim, CA (April 16-20, 2005). Filed in Patent Interference 105,652 (HGS Exhibit 2022).	
VT	Information Disclosure Statement dated February 20, 2007 from file history of the RDF Involved Application. Filed in Patent Interference 105,652 (HGS Exhibit 2023).	
VU	Shen et al., "Construction and Expression of a New Fusion Protein, Thymosin α 1—cBLyS, in <i>E. coli</i> ," <i>Biotech. Lett.</i> , 27:143-148 (2005). Filed in Patent Interference 105,652 (HGS Exhibit 2024).	
VV	Cao et al., "Construction and Characterization of Bi-functional EGFP/sBAFF Fusion Protein," <i>Biochimie</i> , 88:629-635 (2006). Filed in Patent Interference 105,652 (HGS Exhibit 2025).	

Examiner Signature	Date Considered
--------------------	-----------------

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	09/589,288
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Filing Date	June 8, 2000
				First Named Inventor	Guo-Liang Yu
				Group Art Unit	1647
				Examiner Name	Bridget E. Bunner
				Attorney Docket Number	702041
				Client Reference No.	PF343P3C5
Sheet	3	of	4		

VW	Transcript of Deposition of Michael Rosenblum, dated February 26, 2009. Filed in Patent Interference 105,652 (HGS Exhibit 2026).	
VX	Lyu et al., "The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines," <i>Biochem. Pharmacol.</i> , 75:836-846 (2008). Filed in Patent Interference 105,652 (HGS Exhibit 2027).	
VY	Rosenblum et al., "Design, Expression, Purification, and Characterization, <i>in Vitro</i> and <i>in Vivo</i> , of an Antimelanoma Single-chain Fv Antibody Fused to the Toxin Gelonin," <i>Cancer Res.</i> , 63:3995-4002 (2003). Filed in Patent Interference 105,652 (HGS Exhibit 2028).	
VZ	Kim et al., "Overexpression of biologically active VEGF121 fusion proteins in <i>Escherichia coli</i> ," <i>J. Biotechnol.</i> , 128:638-647 (2007). Filed in Patent Interference 105,652 (HGS Exhibit 2029).	
WA	Veenendaal et al., "In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors," <i>Proc. Natl. Acad. Sci.</i> , 99(12):7866-7871 (June 2002). Filed in Patent Interference 105,652 (HGS Exhibit 2030).	
WB	Liu et al., "Targeted delivery of human pro-apoptotic enzymes to tumor cells: <i>In vitro</i> studies describing a novel class of recombinant highly cytotoxic agents," <i>Mol. Cancer Ther.</i> , 2(12):1341-1350 (2003). Filed in Patent Interference 105,652 (HGS Exhibit 2031).	
WC	Lyu et al., "The Growth Factor Toxin Construct rGel/BLyS Specifically Targets Tumor Cells Expressing BAFF-R, TACI, and BCMA," AACR #1517 (poster). Filed in Patent Interference 105,652 (HGS Exhibit 2032).	
WD	<i>Wesley Jessen Corp. v. Bausch & Lomb, Inc.</i> , 209 F. Supp. 2d. 348, 398 (D. Del. 2002), <i>aff'd</i> 56 Fed. Appx. 503 (Fed. Cir. 2003). Filed in Patent Interference 105,652 (HGS Exhibit 2033).	
WE	<i>Bhagwat v. Hrastar</i> , Interference No. 105,516, Paper 67 at 4 (November 7, 2007). Filed in Patent Interference 105,652 (HGS Exhibit 2034).	
WF	Information Disclosure Statement dated September 28, 2006 from file history of the RDF Involved Application. Filed in Patent Interference 105,652 (HGS Exhibit 2035).	
WG	Supplemental Information Disclosure Statement dated March 7, 2007 from file history of the RDF Involved Application. Filed in Patent Interference 105,652 (HGS Exhibit 2036).	
WH	Supplemental Information Disclosure Statement dated May 29, 2008 from file history of the RDF Involved Application. Filed in Patent Interference 105,652 (HGS Exhibit 2037).	
WI	<i>Ex parte Jellá</i> , Appeal No. 2008-1619 (BPAI November 3, 2008). Filed in Patent Interference 105,652 (HGS Exhibit 2038).	
WJ	Declaration of Michael Rosenblum, submitted by RDF on December 12, 2003 in <i>inter partes</i> Reexamination No. 95/000,016 involving U.S. Patent No. 6,376,217, entitled "Fusion Proteins and Polynucleotides Encoding Gelonin Sequences." Filed in Patent Interference 105,652 (HGS Exhibit 2039).	
WK	RDF Power of Attorney from <i>inter partes</i> Reexamination No. 95/000,016. Filed in Patent Interference 105,652 (HGS Exhibit 2041).	
WL	HGS Objections to RDF Evidence filed in Patent Interference 105,652. Filed in the United States Patent Office on January 30, 2009. (HGS Exhibit 2042).	
WM	<i>Chen v. Bouchard</i> Final Decision issued in Patent Interference 103,675. Filed in Patent Interference 105,652 (HGS Exhibit 2043).	

Examiner Signature	Date Considered
--------------------	-----------------

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/589,288
				Filing Date	June 8, 2000
				First Named Inventor	Guo-Liang Yu
				Group Art Unit	1647
				Examiner Name	Bridget E. Bunner
				Attorney Docket Number	702041
Sheet	4	of	4	Client Reference No.	PF343P3C5

WN	Stirpe et al., <i>Biotechnology</i> , 10(4):405-12 (1992). Filed in Patent Interference 105,652 (RDF Exhibit 1008).	
WO	Rosenblum et al., <i>J. Interferon Cytokine Res.</i> , 15(6):547-55 (1995). Filed in Patent Interference 105,652 (RDF Exhibit 1009).	
WP	Rosenblum Declaration dated January 23, 2009. Filed in Patent Interference 105,652 (RDF Exhibit 1010).	
WQ	Rosenblum Curriculum Vitae. Filed in Patent Interference 105,652 (RDF Exhibit 1011).	
WR	Dr. Arthur Chin Louie letter dated September 5, 2001. Filed in Patent Interference 105,652 (RDF Exhibit 1012).	
WS	Copy of page 53 of Mi-ae Lyu notebook dated October 7, 2003. Filed in Patent Interference 105,652 (RDF Exhibit 1013).	
WT	Copy of page 60 of Mi-ae Lyu notebook dated October 17, 2003. Filed in Patent Interference 105,652 (RDF Exhibit 1014).	
WU	Copy of page 1-3 of Lawrence Cheung notebook dated January 27, 2004. Filed in Patent Interference 105,652 (RDF Exhibit 1015).	
WV	Copy of page 23 of Lawrence Cheung notebook dated April 14, 2004. Filed in Patent Interference 105,652 (RDF Exhibit 1016).	
WW	Noelle v. Lederman, 2001 Pat. App. LEXIS 8 (2001). Filed in Patent Interference 105,652 (RDF Exhibit 1017).	
WX	HGS Amendment and Reply dated 8/2/07, U.S. Serial No. 11/054,539. Filed in Patent Interference 105,652 (RDF Exhibit 1018).	
WY	Dr. Arthur Chin Louie letter dated September 5, 2001 with facsimile cover sheet. Filed in Patent Interference 105,652 (RDF Supplemental Exhibit 1012).	
WZ	Yu Miscellaneous Motion 3 filed in Patent Interference 105,652. Filed in the United States Patent Office on May 6, 2009.	

Examiner Signature	/Bridget E. Bunner/	Date Considered	07/10/2009
--------------------	---------------------	-----------------	------------

* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BEB/